Company intelligence / Profile preview

InterVene

Redwood City, California, United Statesintervenek12.com ↗

Ownership: Private
Development stage: Preclinical

Overview

The company has completed development of the Recana catheter system for recanalizing chronically obstructed deep veins and venous stents. It has initiated clinical cases and plans to submit for US market clearance. The technology aims to address significant unmet needs in chronic venous insufficiency and post-thrombotic disease by providing a new tool for vascular specialists. No published pivotal trial results yet.

Therapeutic areas: Cardiovascular
Modalities: Device
Industry: Surgical Medical Devices

Drug pipeline

1 asset

Recana

Pre-clinical

Indications: Chronic venous insufficiency, Deep vein thrombosis, Post-thrombotic syndrome

Partnerships

Treo Ventures (investor/board participation)RiverVest Venture Partners® (investor/board participation)

Beyond the preview

Go deeper on InterVene.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on InterVene.

Explore the full profile